GENOCEA BIOSCIENCES INC (GNCA) Stock Price, Quote, News and Overview
NASDAQ:GNCA - Nasdaq - US3724274010 - Common Stock
GNCA Quote, Performance and Key Statistics
0.051
-0.01 (-15%)
The current stock price of GNCA is 0.051 null. In the past month the price decreased by -80.31%. In the past year, price decreased by -97.8%.
GNCA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GNCA
Company Profile
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is focused on discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Its product candidates include GEN-011 and GEN-009. GEN-011 is an investigational solid tumor cell therapy candidate, which consists of CD4+ and CD8+ neoantigen-targeted peripheral T cells (NPTs) which are specific for up to 30 antigens, designed to limit tumor escape. GEN-011 consists of T cells extracted from the patient’s peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The firm is evaluating its Phase I/IIa of GEN-009.
Company Info
GENOCEA BIOSCIENCES INC
100 Acorn Park Dr
Cambridge MASSACHUSETTS 02140 US
CEO: William Clark
Employees: 74
Company Website: http://www.genocea.com/
Phone: 16178768191.0
GENOCEA BIOSCIENCES INC / GNCA FAQ
What is the stock price of GENOCEA BIOSCIENCES INC today?
The current stock price of GNCA is 0.051 null. The price decreased by -15% in the last trading session.
What is the ticker symbol for GENOCEA BIOSCIENCES INC stock?
The exchange symbol of GENOCEA BIOSCIENCES INC is GNCA and it is listed on the Nasdaq exchange.
On which exchange is GNCA stock listed?
GNCA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GENOCEA BIOSCIENCES INC stock?
9 analysts have analysed GNCA and the average price target is 3.14 null. This implies a price increase of 6060% is expected in the next year compared to the current price of 0.051. Check the GENOCEA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GENOCEA BIOSCIENCES INC worth?
GENOCEA BIOSCIENCES INC (GNCA) has a market capitalization of 3.00M null. This makes GNCA a Nano Cap stock.
How many employees does GENOCEA BIOSCIENCES INC have?
GENOCEA BIOSCIENCES INC (GNCA) currently has 74 employees.
Is GENOCEA BIOSCIENCES INC (GNCA) expected to grow?
The Revenue of GENOCEA BIOSCIENCES INC (GNCA) is expected to decline by -46.87% in the next year. Check the estimates tab for more information on the GNCA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GENOCEA BIOSCIENCES INC (GNCA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GNCA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GNCA, evaluating the profitability, health, valuation and growth aspects
- GENOCEA BIOSCIENCES INC (GNCA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GENOCEA BIOSCIENCES INC (GNCA) Sales and EPS estimates to see what analysts future expectations are.
- GENOCEA BIOSCIENCES INC (GNCA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GENOCEA BIOSCIENCES INC (GNCA) Insider and Institutional Ownership to learn about the owners and their transactions.
- GENOCEA BIOSCIENCES INC (GNCA) Stock Chart to make your own analysis
- GENOCEA BIOSCIENCES INC (GNCA) Latest news and press-releases to stay up to date.
Does GENOCEA BIOSCIENCES INC (GNCA) stock pay dividends?
GNCA does not pay a dividend.
When does GENOCEA BIOSCIENCES INC (GNCA) report earnings?
GENOCEA BIOSCIENCES INC (GNCA) will report earnings on 2022-07-27.
What is the Price/Earnings (PE) ratio of GENOCEA BIOSCIENCES INC (GNCA)?
GENOCEA BIOSCIENCES INC (GNCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).
GNCA Technical Analysis
GNCA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNCA. Both the profitability and financial health of GNCA have multiple concerns.
GNCA Financial Highlights
Over the last trailing twelve months GNCA reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 40.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1947.12% | ||
| ROA | -95.88% | ||
| ROE | N/A | ||
| Debt/Equity | 0.24 |
GNCA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to GNCA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -58.43% and a revenue growth -46.87% for GNCA